Susan Jones
Direttore Tecnico/Scientifico/R&S presso ImmuRx, Inc.
Patrimonio netto: 366 944 $ in data 30/04/2024
Profilo
Susan Dana Jones is the founder of Serenex, Inc., Waratah Pharmaceuticals, Inc., and Gene Solutions LLC.
She currently holds the position of Director at Gene Solutions LLC and Vice President-Research & Development at ImmuRx, Inc. Additionally, she is the Chief Technology Officer at Tourmaline Sub, Inc. and Tourmaline Bio, Inc. starting in 2023.
Prior to her current roles, she served as the Senior Vice President-Product Development at Harpoon Therapeutics, Inc. from 2017 to 2022.
Dr. Jones completed her undergraduate degree at Harvard University and obtained a doctorate from The University of California, San Francisco.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
0.09% | 23/10/2023 | 22 934 ( 0.09% ) | 366 944 $ | 30/04/2024 |
Posizioni attive di Susan Jones
Società | Posizione | Inizio |
---|---|---|
ImmuRx, Inc.
ImmuRx, Inc. BiotechnologyHealth Technology ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH. | Direttore Tecnico/Scientifico/R&S | - |
Gene Solutions LLC
Gene Solutions LLC BiotechnologyHealth Technology Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA. | Direttore/Membro del Consiglio | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Direttore Tecnico/Scientifico/R&S | 01/06/2022 |
Precedenti posizioni note di Susan Jones
Società | Posizione | Fine |
---|---|---|
HARPOON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2022 |
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Fondatore | - |
Waratah Pharmaceuticals, Inc.
Waratah Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million. | Fondatore | - |
Formazione di Susan Jones
Harvard University | Undergraduate Degree |
The University of California, San Francisco | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
HARPOON THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
ImmuRx, Inc.
ImmuRx, Inc. BiotechnologyHealth Technology ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH. | Health Technology |
Waratah Pharmaceuticals, Inc.
Waratah Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million. | Health Technology |
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Health Technology |
Gene Solutions LLC
Gene Solutions LLC BiotechnologyHealth Technology Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA. | Health Technology |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
- Borsa valori
- Insiders
- Susan Jones